Bernard Moss
Cited by
Cited by
Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase
TR Fuerst, EG Niles, FW Studier, B Moss
Proceedings of the National Academy of Sciences 83 (21), 8122-8126, 1986
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
RR Amara, F Villinger, JD Altman, SL Lydy, SP O'Neil, SI Staprans, ...
Science 292 (5514), 69-74, 2001
HIV-specific cytotoxic T lymphocytes in seropositive individuals
BD Walker, S Chakrabarti, B Moss, TJ Paradis, T Flynn, AG Durno, ...
Nature 328 (6128), 345-348, 1987
Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques
S Chakrabarti, K Brechling, B Moss
Molecular and cellular biology 5 (12), 3403-3409, 1985
Vaccinia virus: a selectable eukaryotic cloning and expression vector
M Mackett, GL Smith, B Moss
Proceedings of the National Academy of Sciences 79 (23), 7415-7419, 1982
In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity
RL Willey, DH Smith, LA Lasky, TS Theodore, PL Earl, B Moss, DJ Capon, ...
Journal of virology 62 (1), 139-147, 1988
General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes
M Mackett, GL Smith, B Moss
Journal of virology 49 (3), 857-864, 1984
Nonreplicating vaccinia vector efficiently expresses recombinant genes
G Sutter, B Moss
Proceedings of the National Academy of Sciences 89 (22), 10847-10851, 1992
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety
B Moss
Proceedings of the National Academy of Sciences 93 (21), 11341-11348, 1996
Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein
JD Lifson, MB Feinberg, GR Reyes, L Rabin, B Banapour, S Chakrabarti, ...
Nature 323 (6090), 725-728, 1986
Vaccination of chimpanzees against infection by the hepatitis C virus.
QL Choo, G Kuo, R Ralston, A Weiner, D Chien, G Van Nest, J Han, ...
Proceedings of the National Academy of Sciences 91 (4), 1294-1298, 1994
New mammalian expression vectors
B Moss, O Elroy-Stein, T Mizukami, WA Alexander, TR Fuerst
Nature 348 (6296), 91-92, 1990
Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes
JW Yewdell, JR Bennink, GL Smith, B Moss
Proceedings of the National Academy of Sciences 82 (6), 1785-1789, 1985
The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis.
B Rehermann, P Fowler, J Sidney, J Person, A Redeker, M Brown, ...
The Journal of experimental medicine 181 (3), 1047-1058, 1995
Vaccinia virus: a tool for research and vaccine development
B Moss
Science 252 (5013), 1662-1667, 1991
A cytoskeletal structure with associated polyribosomes obtained from HeLa cells
R Lenk, L Ransom, Y Kaufmann, S Penman
Cell 10 (1), 67-78, 1977
Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas-and TNFR1-induced apoptosis
J Bertin, RC Armstrong, S Ottilie, DA Martin, Y Wang, S Banks, GH Wang, ...
Proceedings of the National Academy of Sciences 94 (4), 1172-1176, 1997
Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen
GL Smith, M Mackett, B Moss
Nature 302 (5908), 490-495, 1983
Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype
RML Buller, GL Smith, K Cremer, AL Notkins, B Moss
Nature 317 (6040), 813-815, 1985
gp100/pmel 17 is a murine tumor rejection antigen: induction of “self”-reactive, tumoricidal T cells using high-affinity, altered peptide ligand
WW Overwijk, A Tsung, KR Irvine, MR Parkhurst, TJ Goletz, K Tsung, ...
The Journal of experimental medicine 188 (2), 277-286, 1998
The system can't perform the operation now. Try again later.
Articles 1–20